Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | PIK-93 | 1 | 72 | 0.32 | 5519.0 | 5875.8 | 1443.3 | -0.495 | 0.939 | 0.939 | 2.025 | BT20 PIK93 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 1.0 | 5741.0 | 6240.0 | 1443.3 | 0.0 | 0.923 | 0.920 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | PIK-93 | 1 | 72 | 1.0 | 4892.3 | 5875.8 | 1443.3 | 0.0 | 0.827 | 0.833 | 2.025 | BT20 PIK93 0 1 |
| BT-549 | Pictilisib | 1 | 72 | 0.01 | 5399.3 | 5311.0 | 1554.9 | -2.0 | 1.020 | 1.020 | 1.772 | BT549 GDC0941 0 1 72 |
| BT-20 | PIK-93 | 1 | 72 | 3.2 | 2878.0 | 5875.8 | 1443.3 | 0.505 | 0.406 | 0.490 | 2.025 | BT20 PIK93 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 3.2 | 5408.0 | 6240.0 | 1443.3 | 0.505 | 0.869 | 0.867 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 0.001 | 3625.0 | 5856.5 | 1443.3 | -3.0 | 0.577 | 0.619 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | AZD-6482 | 1 | 72 | 3.2 | 2032.7 | 5948.8 | 1443.3 | 0.505 | 0.182 | 0.342 | 2.043 | BT20 AZD6482 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 0.0032 | 3775.5 | 5856.5 | 1443.3 | -2.49 | 0.609 | 0.645 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.001 | 3773.0 | 5781.0 | 1443.3 | -3.0 | 0.616 | 0.653 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 0.01 | 3763.8 | 5856.5 | 1443.3 | -2.0 | 0.607 | 0.643 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | AZD8055 | 1 | 72 | 0.001 | 5501.0 | 5941.5 | 1443.3 | -3.0 | 0.926 | 0.926 | 2.041 | BT20 AZD8055 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 0.032 | 3662.3 | 5856.5 | 1443.3 | -1.49 | 0.585 | 0.625 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.0032 | 3719.8 | 5781.0 | 1443.3 | -2.49 | 0.605 | 0.643 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 0.1 | 3647.3 | 5856.5 | 1443.3 | -1.0 | 0.582 | 0.623 | 2.021 | BT20 Rapamycin 0 1 |
| BT-549 | AS605240 | 1 | 72 | 0.032 | 5197.3 | 5429.5 | 1554.9 | -1.49 | 0.952 | 0.957 | 1.804 | BT549 AS605240 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.32 | 3778.3 | 5856.5 | 1443.3 | -0.495 | 0.610 | 0.645 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.01 | 3784.5 | 5781.0 | 1443.3 | -2.0 | 0.619 | 0.655 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 1.0 | 3619.3 | 5856.5 | 1443.3 | 0.0 | 0.576 | 0.618 | 2.021 | BT20 Rapamycin 0 1 |
| BT-549 | AS605240 | 1 | 72 | 3.2 | 4915.0 | 5429.5 | 1554.9 | 0.505 | 0.893 | 0.905 | 1.804 | BT549 AS605240 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 3.2 | 3597.5 | 5856.5 | 1443.3 | 0.505 | 0.571 | 0.614 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.032 | 3677.3 | 5781.0 | 1443.3 | -1.49 | 0.595 | 0.636 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | TGX221 | 1 | 72 | 0.001 | 5503.5 | 5723.8 | 1443.3 | -3.0 | 0.961 | 0.962 | 1.988 | BT20 TGX221 0 1 |
| BT-549 | GDC-0980 | 1 | 72 | 0.01 | 5203.0 | 5343.8 | 1554.9 | -2.0 | 0.970 | 0.974 | 1.781 | BT549 GDC0980 0 1 72 |
| BT-549 | GDC-0980 | 1 | 72 | 0.0032 | 5411.8 | 5343.8 | 1554.9 | -2.49 | 1.010 | 1.010 | 1.781 | BT549 GDC0980 0 1 72 |